Meeting
2020 Genitourinary Cancers Symposium
Relative risk of pneumonitis associated with first-line use of immune checkpoint inhibitors in advanced renal cell carcinoma.
Authors
Nusrat Jahan
Texas Tech University Health Sciences Center, Lubbock, TX
Nusrat Jahan , Francis Mogollon-Duffo , Srikala Meda , Fred L. Hardwicke , Lukman Aderoju Tijani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 676)
Abstract #
676
Poster Bd #
F18
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Relative risk of hematological toxicities in patients with advanced renal cell carcinoma treated with upfront immune checkpoint inhibitors.
First Author: Nusrat Jahan
Poster
2022 ASCO Annual Meeting
First-line therapy for elderly patients with advanced renal cell carcinoma (aRCC): A systemic review and network meta-analysis.
First Author: Yu Fujiwara
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
First Author: Kevin Yan
Poster
2024 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
First Author: Viktor Grünwald